<\/p>\n\n\n\n
<\/p>\n\n\n\n
Missoula, MT \u2013 March 5, 2026<\/em> <\/strong>\u2013 Inimmune Corporation, a clinical-stage biotechnology company developing next-generation immunotherapies, today announced the appointments of Ferdinand Massari, M.D., as Chief Medical Officer (CMO), and Ryan McMillian as Head of Financial Strategy. The appointments strengthen the leadership team as Inimmune advances its lead allergic rhinitis program, INI-2004, toward key milestones and planned expansion into allergic asthma and food allergy.<\/p>\n\n\n\n \u201cInimmune is entering an important phase of growth as we continue to advance our pipeline and broaden our capabilities,\u201d said David Burkhart, Ph.D., Chief Executive Officer of Inimmune Corporation. \u201cAs we look ahead to upcoming clinical milestones, Dr. Massari\u2019s deep clinical development expertise and Mr. McMillian\u2019s financial leadership position us to execute with focus and discipline as we work to bring innovative immunotherapies to patients who urgently need better options. We\u2019re pleased to welcome them to the team.\u201d<\/p>\n\n\n\n Dr. Massari brings more than two decades of experience in clinical development and translational medicine across immunology and inflammatory diseases and has led high-performing clinical teams in both biotechnology and large pharmaceutical settings. Earlier in his career, he held senior clinical and medical leadership roles at Shire, Pfizer, Pharmacia, and Merck, supporting the development and commercialization of therapies across multiple therapeutic areas. As CMO, Dr. Massari will lead Inimmune\u2019s clinical strategy and execution, including continued development of INI-2004, the company\u2019s lead allergy program, and planned expansion into allergic asthma and food allergy. Dr. Massari succeeds Dr. Jon Ruckle, who successfully advanced Inimmune\u2019s oncology and allergy programs through Phase 1 clinical trials. <\/p>\n\n\n\n \u201cThe Phase 2 progress in allergic rhinitis underscores the potential of INI-2004 as a differentiated, disease-modifying therapy,\u201d said Dr. Massari. \u201cI\u2019m pleased to join Inimmune at this pivotal time and help advance the program into its next stage of clinical development.\u201d<\/p>\n\n\n\n Mr. McMillian joins Inimmune as Head of Financial Strategy, bringing more than 20 years\u2019 experience in biotech finance, corporate strategy, and capital formation, including more than $250 million in fundraising for life sciences companies. Previously, he served as Head of U.S. Finance at Alexion Pharmaceuticals, where he provided financial leadership and supported multiple orphan drug launches. He was also part of the investment and advisory ecosystem at Yale Ventures. Earlier in his career, Mr. McMillian held corporate finance and banking roles at GE Capital. At Inimmune, Mr. McMillian will lead financial planning and strategic initiatives to support Inimmune\u2019s expanding clinical portfolio and long-term growth strategy.<\/p>\n\n\n\n \u201cInimmune has built a compelling clinical foundation in allergic disease,\u201d said Mr. McMillian. \u201cI look forward to helping the company execute its growth strategy, strengthen financial readiness, and support the advancement of therapies that have the potential to meaningfully improve patients\u2019 lives.\u201d<\/p>\n\n\n\n The new leadership appointments support Inimmune\u2019s strategic focus to expand development of its rapid, disease-modifying immunotherapy into allergic asthma and food allergy \u2014 conditions affecting millions worldwide and carrying a substantial clinical and economic burden.<\/p>\n\n\n\n About Inimmune Corporation<\/strong>
Inimmune is a clinical-stage biotechnology company focused on the discovery and development of next-generation immunotherapies for the treatment of infectious diseases, allergy, and cancer. Leveraging its proprietary technology platforms, Inimmune is dedicated to creating safe and effective treatments that harness the immune system to improve patient outcomes. For more information, follow us on LinkedIn<\/a> and visit www.inimmune.com\/<\/p>\n\n\n\n